Vireo Growth (VREOF) Other Non-Current Liabilities (2021 - 2026)
Vireo Growth (VREOF) reported Other Non-Current Liabilities of $30.0 million for Q1 2026, up 80376.42% on a YoY basis from N/an in Q1 2025, and up 1400.0% sequentially from $2.0 million in Q4 2025.
Vireo Growth (VREOF) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 6 years of Other Non-Current Liabilities data on file, last reported at $30.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 80376.42% year-over-year to $30.0 million; the trailing twelve-month figure through Mar 2026 stood at $30.0 million (up 80376.42% YoY), and the FY2025 full-year result was $2.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $30.0 million in Q1 2026, from $2.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $30.0 million in Q1 2026 to a low of $1613.0 in Q4 2022.
- A 5-year average of $4.1 million and a median of $216938.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities declined 8.66% in 2024 and surged 80376.42% in 2026, its largest moves.
- Tracing VREOF's Other Non-Current Liabilities over 5 years: stood at $1613.0 in 2022, then jumped by 7454.0% to $121846.0 in 2023, then soared by 78.04% to $216938.0 in 2024, then surged by 821.92% to $2.0 million in 2025, then surged by 1400.0% to $30.0 million in 2026.
- Business Quant data shows VREOF's Other Non-Current Liabilities at $30.0 million in Q1 2026, $2.0 million in Q4 2025, and $1.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.00 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 10.63 Mn |
| Mar 31, 2025 | 37,278.00 |
| Sep 30, 2024 | 216,938.00 |
| Jun 30, 2024 | 196,598.00 |
| Dec 31, 2023 | 121,846.00 |
| Sep 30, 2023 | 235,577.00 |
| Jun 30, 2023 | 215,237.00 |
| Dec 31, 2022 | 1,613.00 |
| Sep 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 3.71 Mn |
| Mar 31, 2021 | 5.24 Mn |